SEARCH

SEARCH BY CITATION

References

  • 1
    Benker G, Reinwein D, Kahaly G et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin. Endocrinol. (Oxf.) 1998; 49: 451457.
  • 2
    Senyurek Giles Y, Tunca F, Boztepe H, Kapran Y, Terzioglu T, Tezelman S. The risk factors for malignancy in surgically treated patients for Graves’ disease, toxic multinodular goiter, and toxic adenoma. Surgery 2008; 144: 10281036; discussion 36–7.
  • 3
    Karagulle E, Yildirim S, Karakayali F, Turk E, Moray G. Malignancy rates in operated patients with hyperthyroidism in an area of endemic goiter. Int. Surg. 2009; 94: 325329.
  • 4
    Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA. Thyroidectomy remains an effective treatment option for Graves’ disease. Am. J. Surg. 2006; 191: 400405.
  • 5
    Berker D, Isik S, Ozuguz U et al. Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism. Endocrine 2011; 39: 1320.
  • 6
    Dănilă R, Karakas E, Osei-Agyemang T, Hassan I. Outcome of incidental thyroid carcinoma in patients undergoing surgery for Graves’ disease. Rev. Med. Chir. Soc. Med. Nat. Iasi 2008; 112: 115118.
  • 7
    Phitayakorn R, McHenry CR. Incidental thyroid carcinoma in patients with Graves’ disease. Am. J. Surg. 2008; 195: 292297; discussion 97.
  • 8
    Mishra A, Mishra SK. Thyroid nodules in Graves’ disease: implications in an endemically iodine deficient area. J. Postgrad. Med. 2001; 47: 244247.
  • 9
    Kraimps JL, Bouin-Pineau MH, Mathonnet M et al. Multicentre study of thyroid nodules in patients with Graves’ disease. Br. J. Surg. 2000; 87: 11111113.
  • 10
    Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009; 20: 7586.
  • 11
    Burgess JR, Dwyer T, McArdle K, Tucker P, Shugg D. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978–1998) during a transition from iodine sufficiency to iodine deficiency. J. Clin. Endocrinol. Metab. 2000; 85: 15131517.
  • 12
    Karamanakos SN, Markou KB, Panagopoulos K et al. Complications and risk factors related to the extent of surgery in thyroidectomy. Results from 2043 procedures. Hormones (Athens) 2010; 9: 318325.
  • 13
    Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J. Surg. 2010; 34: 12611264.
  • 14
    Barakate MS, Agarwal G, Reeve TS, Barraclough B, Robinson B, Delbridge LW. Total thyroidectomy is now the preferred option for the surgical management of Graves’ disease. ANZ J. Surg. 2002; 72: 321324.
  • 15
    Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J. Clin. Endocrinol. Metab. 2011; 96: 592599.
  • 16
    Bahn RS, Burch HB, Cooper DS et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 2011; 17: 456520.
  • 17
    Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur. J. Endocrinol. 2008; 158: 6975.
  • 18
    Sawka AM, Thabane L, Parlea L et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009; 19: 451457.
  • 19
    Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 117: 44394446.
  • 20
    Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007; 109: 19721979.
  • 21
    Verburg FA, Luster M, Lassmann M, Reiners C. (131)I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. Nuklearmedizin 2011; 50: 9399; quiz N20.
  • 22
    Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann. Surg. 1998; 228: 320330.
  • 23
    Ebrahimi H, Edhouse P, Lundgren CI et al. Does autoimmune thyroid disease affect parathyroid autotransplantation and survival? ANZ J. Surg. 2009; 79: 383385.
  • 24
    Page C, Strunski V. Parathyroid risk in total thyroidectomy for bilateral, benign, multinodular goitre: report of 351 surgical cases. J. Laryngol. Otol. 2007; 121: 237241.
  • 25
    Serpell JW, Phan D. Safety of total thyroidectomy. ANZ J. Surg. 2007; 77: 1519.
  • 26
    Jarhult J, Andersson PO, Duncker L. Alternating from subtotal thyroid resection to total thyroidectomy in the treatment of Graves’ disease prevents recurrences but increases the frequency of permanent hypoparathyroidism. Langenbecks Arch. Surg. 2012; 397: 407412.
  • 27
    Sitges-Serra A, Ruiz S, Girvent M, Manjon H, Duenas JP, Sancho JJ. Outcome of protracted hypoparathyroidism after total thyroidectomy. Br. J. Surg. 2011; 97: 16871695.
  • 28
    Grodski S, Serpell J. Evidence for the role of perioperative PTH measurement after total thyroidectomy as a predictor of hypocalcemia. World J. Surg. 2008; 32: 13671373.
  • 29
    Tanriover O, Comunoglu N, Eren B et al. Occult papillary thyroid carcinoma: prevalence at autopsy in Turkish people. Eur. J. Cancer Prev. 2011; 20: 308312.
  • 30
    Kovacs GL, Gonda G, Vadasz G et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 2005; 15: 152157.
  • 31
    Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am. J. Otolaryngol. 2005; 26: 8790.
  • 32
    Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18 445 cases. Ann. Surg. 2011; 254: 653660.
  • 33
    Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Horm. Metab. Res. 2012; 44: 255262.